Keywords
stringent complete response
myeloma biomarker
How to Cite
Abstract
Monoclonal gammopathies (MGs) are characterized by the clonal production of immunoglobulins or their subunits, including free light chains (FLCs). The quantification of serum FLCs has proven to be a highly sensitive tool for the early diagnosis, monitoring, and prognosis of various MGs, such as monoclonal gammopathy of undetermined significance, multiple myeloma and AL amyloidosis. Their short half-life allows for a dynamic assessment of therapeutic response and early detection of relapse. Several commercial methods are available for FLC quantification, based on either secondary immunologic interaction (immunoturbidimetry or immunonephelometry) or primary interaction (ELISA), which show variability in analytical performance and are not interchangeable. Clinical interpretation of the results requires consideration of both methodological aspects and individual pathophysiological factors, such as renal function and polyclonal immunoglobulin synthesis. Consistent follow-up within the same laboratory is essential to ensure comparability and reliability of results in the clinical management of patients.
References
Rajkumar SV, Dimopoulos MA, Palumbo A y col. International Myeloma Working Group updated criterio for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548. https://doi.org/10.1016/S1470-2045(14)70442-5.
Keren DF, Bocsi G, Billman BL y col. Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies: Guideline From the College of American Pathologists in Collaboration With the American Association for Clinical Chemistry and the American Society for Clinical Pathology. Arch Pathol Lab Med. 2022;146 (5):575-590. https://doi.org/10.5858/arpa.2020-0794-CP.
Rajkumar SV, Kyle RA, Therneau TM y col. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812-817. https://doi.org/10.1182/blood-2005-03-1038.
Mateos MV, Kumar S, Dimopoulos MA y col. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10,102. https://doi.org/10.1038/s41408-020-00366-3.
Kumar S, Paiva B, Anderson KC y col. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346. https://doi.org/10.1016/S1470-2045(16)30206-6.
Shanley C y Duarte P. Sociedad Argentina de Hematología. Gammapatías monoclonales: Guías de diagnóstico y tratamiento. Buenos Aires: Sociedad Argentina de Hematología; 2023.
Schieferdecker A, Hörber S, Ums M y col. Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma. Blood Cancer J. 2020;10(1):2. https://doi.org/10.1038/s41408-019-0267-8.
Katzmann JA, Clark RJ, Abraham RS y col. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(9):1437-1444.
Einarsson Long T, Rognvaldsson S, Thorsteinsdottir S y col. New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance. JAMA Oncol. 2025;11(7):e1-e9. https://doi.org/10.1001/jamaoncol.2025.1285.
Hutchison CA, Harding S, Hewins P y col. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1684-1690. https://doi.org/10.2215/CJN.02290508.
Long TE, Indridason OS, Palsson R y col. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study. Blood Cancer J. 2022;12(9):133. https://doi.org/10.1038/s41408-022-00732-3.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar